p-ISSN: 1301-4021
e-ISSN: 2147-2548
Editor-in-Chief
Haner Direskeneli
2017 Volume 9
 
 
Deomed Yayıncılık
 
 
 
Volume 7, Supplement 1, September 2015
Page(s): S1-S7
 
Review
Received: May 21, 2015; Accepted: July 20, 2015; Published online: November 25, 2015
doi:10.2399/raed.15.S1S1; Copyright © 2015 Rheumatology Association of Turkey (TRD).
Certolizumab pegol for the treatment of rheumatoid arthritis
Nevsun İnanç
Marmara Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Romatoloji Bilim Dalı, İstanbul
Summary
The development of tumour necrosis factor-alpha (TNF-alpha) inhibitors is an important progress in the treatment of rheumatoid arthritis (RA). As a new anti-TNF alpha treatment drug, certolizumab pegol (CZP) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that neutralizes TNF- alpha. In randomized, controlled trials, CZP was evaluated either as mono-therapy or combination with MTX or other DMARDs in mild to severely active RA. Data from these trials showed that with rapid onset of action CZP is effective in reducing the disease activity, disability and also inhibiting the radiographic progression. The beneficial effect of CZP was also demonstrated even in higher response rate than the previous studies in RA patients failed to other anti-TNF drugs. The meta-analysis and comparison trials indicated that CZP was effective for the improvement of disease activity scores, physical function, pain and fatigue relative to other biologic drugs. The randomized, controlled clinical trials and long term extension phases of these studies strengthen the use of CZP in patients with moderate to severely active RA as either mono therapy or preferably in combination with DMARDs after a loading regime (0-2-4 weeks 400 mg) to continue with 200 mg CZP every 2 weeks.
Keywords: Rheumatoid arthritis, certolizumab pegol
 
 
Reklam
 
   
RAED Dergisi / RAED Journal

Türkiye Romatoloji Araştırma ve Eğitim Derneği (RAED) yayın organıdır. Deomed Yayıncılık tarafından yayımlanmaktadır. / Official Publication of the Society for Education and Research in Rheumatology (RAED), Turkey. Published by Deomed Publishing. Copyright © 2017, RAED.
Creative Commons License
RAED Dergisi çevrimiçi (online) sürümünde yayımlanan akademik içeriğin kullanım hakları, ilgili içerikte tersi belirtilmediği sürece Deomed Yayıncılık tarafından Creative Commons Attribution-NoCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) lisansı aracılığıyla bedelsiz sunulmaktadır. / Except where otherwise noted, academic content of this online version of the journal by Deomed Publishing is licensed under the terms of Creative Commons Attribution-NoCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) License.